A Phase 4 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 18 sites in Japan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 47th largest by enrollment, is one of 13 that started in 2020, is one of 50 in phase 4, and was the 82nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 65th largest by enrollment of the 96 interventional ones that give a count, is one of 5 that started in 2020, is one of 9 in phase 4, and was the 120th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition compared to placebo in elderly patients with T2DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(HbA1c) ≥7.0% and ≤10.0% for patients at Visit 1 (screening). If the patient is on treatment with oral antidiabetic drug(s) potentially associated with severe hypoglycaemia (e.g., sulfonylurea or glinides), the following HbA1c value is used as criterion
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin
Drug: Placebo
Empagliflozin
Placebo
Change in HbA1c From Baseline After 52 Weeks of Treatment
Change in glycated hemoglobin (HbA1c) (in units of %) from baseline after 52 weeks of treatment was modelled using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) which included fixed classification effects for treatment, gender, baseline renal function, visit and visit-by-treatment interaction, and a linear covariate for baseline HbA1c and age. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.The Least Squares Mean (Standard Error) after 52 weeks of treatment is reported.
Time frame: Change in HbA1c from baseline after 52 weeks of treatment was calculated using the MMRM model which is a longitudinal analyses and it incorporates HbA1c values from baseline and after 4 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks of treatment.
Change of Muscle Mass From Baseline to Week 52
Muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of muscle mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline muscle mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52
Change of Body Fat Measurement From Baseline to Week 52
Body fat mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of body fat measurement from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline body fat measurement, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52
Change of Lean Body Mass From Baseline to Week 52
Lean body mass (fat-free mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of lean body mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline lean body mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52.
Change of Total Body Water From Baseline to Week 52
Total body water was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of total body water from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline total body water, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52.
Change of Bone Mineral Content From Baseline to Week 52
Bone mineral content (estimated bone mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of bone mineral content from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline bone mineral content, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52.
Change of Skeletal Muscle Index From Baseline to Week 52
Skeletal muscle index is calculated by dividing the limb muscle mass (kg) by the square of the height (m2). The limb muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of skeletal muscle index from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline skeletal muscle index, age, baseline glycated hemoglobin (HbA1c), baseline body mass index as linear covariates and sex, treatment as fixed effects. "Baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52.
Change of Grip Strength From Baseline to Week 52
A Smedley-type dynamometer was used to measure grip strength. The site staff instructed the patient to adjust the grip width so that the second joint of the index finger is approximately 90 degrees (almost right angle). The site staff asked the patient to be careful not to touch the body or clothes with hand while keeping arms down naturally. The site staff made sure that the patient does not wave the grip dynamometer. Grip strength was measured twice alternately left and right. Change of grip strength from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline grip strength, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52.
Change of Time in the 5-time Chair Stand Test From Baseline to Week 52
For the stand test patients fold their arms across their chest and try to stand up once from a chair. If patients can stand from a chair, they repeat same action five times. It is measured the time required to perform five rise from a chair to an upright position as fast as possible without the use of arms. Change of time in the 5-time chair stand test from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline 5-time chair stand test, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
Time frame: At baseline and at Week 52.
This randomised, double-blind, placebo-controlled, parallel group, multicentre trial compared 10 mg empagliflozin with placebo after 52 weeks in elderly Japanese patients with Type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
| Milestone | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Started | 64 | 65 |
| Completed | 58 | 61 |
| Not completed | 6 | 4 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Adverse event | 3 | 3 |
Change in glycated hemoglobin (HbA1c) (in units of %) from baseline after 52 weeks of treatment was modelled using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) which included fixed classification effects for treatment, gender, baseline renal function, visit and visit-by-treatment interaction, and a linear covariate for baseline HbA1c and age. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.The Least Squares Mean (Standard Error) after 52 weeks of treatment is reported.
| percentage of glycated hemoglobin | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change in HbA1c From Baseline After 52 Weeks of Treatment | -0.12 ± 0.08 | -0.69 ± 0.07 |
Muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of muscle mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline muscle mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Muscle Mass From Baseline to Week 52 | -0.96 ± 0.36 | -1.57 ± 0.35 |
Body fat mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of body fat measurement from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline body fat measurement, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Body Fat Measurement From Baseline to Week 52 | 0.08 ± 0.29 | -1.77 ± 0.28 |
Lean body mass (fat-free mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of lean body mass from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline lean body mass, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Lean Body Mass From Baseline to Week 52 | -1.08 ± 0.27 | -1.61 ± 0.26 |
Total body water was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of total body water from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline total body water, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Total Body Water From Baseline to Week 52 | -0.72 ± 0.21 | -1.35 ± 0.21 |
Bone mineral content (estimated bone mass) was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of bone mineral content from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline bone mineral content, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Bone Mineral Content From Baseline to Week 52 | -0.06 ± 0.02 | -0.09 ± 0.01 |
Skeletal muscle index is calculated by dividing the limb muscle mass (kg) by the square of the height (m2). The limb muscle mass was estimated via bioelectrical impedance analysis (BIA) which is a commonly used method for estimating body composition, and it assesses body composition by passing a very small current through the body and assessing differences in impedance caused by the fact that fat and lean tissues have different electrical properties. To measure the body composition the patient barefoot stood on the bench evenly on the toe and heel electrodes and held the grip on each hand. Change of skeletal muscle index from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline skeletal muscle index, age, baseline glycated hemoglobin (HbA1c), baseline body mass index as linear covariates and sex, treatment as fixed effects. "Baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram/meter^2 (kg/m^2) | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Skeletal Muscle Index From Baseline to Week 52 | -0.245 ± 0.064 | -0.326 ± 0.062 |
A Smedley-type dynamometer was used to measure grip strength. The site staff instructed the patient to adjust the grip width so that the second joint of the index finger is approximately 90 degrees (almost right angle). The site staff asked the patient to be careful not to touch the body or clothes with hand while keeping arms down naturally. The site staff made sure that the patient does not wave the grip dynamometer. Grip strength was measured twice alternately left and right. Change of grip strength from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline grip strength, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| kilogram | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Grip Strength From Baseline to Week 52 | -0.6 ± 0.3 | -0.9 ± 0.3 |
For the stand test patients fold their arms across their chest and try to stand up once from a chair. If patients can stand from a chair, they repeat same action five times. It is measured the time required to perform five rise from a chair to an upright position as fast as possible without the use of arms. Change of time in the 5-time chair stand test from baseline to Week 52 was modelled using an Analysis of Covariance (ANCOVA) which included baseline 5-time chair stand test, age, baseline glycated hemoglobin (HbA1c), baseline body mass index (BMI) as linear covariates and sex, treatment as fixed effects. The term "baseline" refers to the last observed measurement prior to the administration of any randomised trial medication.
| seconds | Placebo | Empagliflozin 10 mg |
|---|---|---|
| Change of Time in the 5-time Chair Stand Test From Baseline to Week 52 | -0.9 ± 0.3 | -0.9 ± 0.3 |
Collected over From the administration of first dose of randomised trial medication until treatment stop +7 days of residual effect period, up to 378 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/64 (1.6%) | 8/64 (12.5%) | 13/64 (20.3%) |
| Empagliflozin 10mg | 0/65 (0%) | 8/65 (12.3%) | 14/65 (21.5%) |
| Event | Placebo | Empagliflozin 10mg |
|---|---|---|
| Femoral neck fractureInjury, poisoning and procedural complications | 2/64 | 0/65 |
| CataractEye disorders | 1/64 | 1/65 |
| DeathGeneral disorders | 1/64 | 0/65 |
| Brain contusionInjury, poisoning and procedural complications | 1/64 | 0/65 |
| Rib fractureInjury, poisoning and procedural complications | 1/64 | 0/65 |
| Traumatic haemothoraxInjury, poisoning and procedural complications | 1/64 | 0/65 |
| Facial paralysisNervous system disorders | 1/64 | 0/65 |
| Optic neuritisNervous system disorders | 1/64 | 0/65 |
| Atrial fibrillationCardiac disorders | 0/64 | 1/65 |
| Exfoliation glaucomaEye disorders | 0/64 | 1/65 |
| Event | Placebo | Empagliflozin 10mg |
|---|---|---|
| ConstipationGastrointestinal disorders | 3/64 | 7/65 |
| DiarrhoeaGastrointestinal disorders | 4/64 | 0/65 |
| NasopharyngitisInfections and infestations | 4/64 | 3/65 |
| PyrexiaGeneral disorders | 3/64 | 4/65 |
Full Analysis Set (FAS): This set included all patients randomised, treated with at least one dose of trial medication, and with a baseline and at least one on-treatment glycated haemoglobin (HbA1c) value.
| Age, Continuous(years) | Placebo | Empagliflozin 10 mg | Total |
|---|---|---|---|
| Mean | 74.0 ± 5.1 | 74.2 ± 4.9 | 74.1 ± 5.0 |
| Sex: Female, Male(Participants) | Placebo | Empagliflozin 10 mg | Total |
|---|---|---|---|
| Female | 19 | 16 | 35 |
| Male | 44 | 48 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Empagliflozin 10 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 63 | 64 | 127 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Empagliflozin 10 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 63 | 64 | 127 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Percentage of glycated haemoglobin (HbA1c)(Percentage of glycated haemoglobin) | Placebo | Empagliflozin 10 mg | Total |
|---|---|---|---|
| Mean | 7.6 ± 0.5 | 7.6 ± 0.5 | 7.6 ± 0.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'
Data sharing details ↗ · www.mystudywindow.com
Ran from Oct 2020 to primary completion in Aug 2022, 22 months.
Results were first posted in Mar 2024, 1 year 6 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 22 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin